, NFS and TSvdW contributed to study monitoring, 2019.
, , 2019.
, Fourth WHO report in neglected tropical disease; integrating NTD into global health and development, vol.17, 2019.
Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus, Lancet Glob Health, vol.7, pp.912-934, 2019. ,
Buruli ulcer: here today but where tomorrow?, Lancet Glob Health, vol.7, pp.821-843, 2019. ,
Laboratory confirmation of Buruli ulcer cases in Ghana, PLoS Negl Trop Dis, vol.12, p.6560, 2008. ,
The paediatric participation scale measuring participation restrictions among former Buruli ulcer patients under the age of 15 in Ghana and Benin: development and first validation results, PLoS Negl Trop Dis, vol.13, p.7273, 2019. ,
Increased severity and spread of Mycobacterium ulcerans, southeastern Australia, Emerg Infect Dis, vol.24, pp.58-64, 2018. ,
, Epidemiology of Buruli ulcer infections, vol.24, pp.1988-97, 2018.
Efficacy of the combination rifampinstreptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans, Antimicrob Agents Chemother, vol.49, pp.3182-86, 2005. ,
Beliefs and attitudes toward Buruli ulcer in Ghana, Am J Trop Med Hyg, vol.67, pp.207-220, 2002. ,
Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients, Trop Med Int Health, vol.10, pp.1251-57, 2005. ,
Clinical epidemiology of laboratoryconfirmed Buruli ulcer in Benin: a cohort study, Lancet Glob Health, vol.2, pp.422-452, 2014. ,
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease, Antimicrob Agents Chemother, vol.54, pp.3678-85, 2010. ,
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial, Lancet, vol.375, pp.664-72, 2010. ,
Long term streptomycin toxicity in the treatment of Buruli ulcer: followup of participants in the BURULICO drug trial, PLoS Negl Trop Dis, vol.8, p.2739, 2014. ,
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice, Antimicrob Agents Chemother, vol.51, pp.3737-3776, 2007. ,
Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice, PLoS Negl Trop Dis, vol.5, p.933, 2011. ,
Clinical and bacteriological efficacy of rifampinstreptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease, Antimicrob Agents Chemother, vol.58, pp.1161-66, 2014. ,
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin, Clin Infect Dis, vol.52, pp.94-96, 2011. ,
statement: updated guidelines for reporting parallel group randomised trials, PLoS Med, vol.7, p.1000251, 2010. ,
, WHO. Facilities involved in Buruli ulcer clinical trial 2012-2015 in Ghana and Benin, vol.17, 2012.
Buruli ulcer control in a highly endemic district in Ghana: role of communitybased surveillance volunteers, Am J Trop Med Hyg, vol.92, pp.115-132, 2015. ,
Contribution of the community health volunteers in the control of Buruli ulcer in Bénin, PLoS Negl Trop Dis, vol.8, p.3200, 2014. ,
Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease, Clin Infect Dis, vol.48, pp.1055-64, 2009. ,
Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens, PLoS One, vol.9, p.89407, 2014. ,
Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection, Clin Infect Dis, vol.54, pp.519-545, 2012. ,
Former buruli ulcer patients' experiences and wishes may serve as a guide to further improve buruli ulcer management, PLoS Negl Trop Dis, vol.10, p.5261, 2016. ,
Burden and historical trend of buruli ulcer prevalence in selected communities along the Offin River of Ghana, PLoS Negl Trop Dis, vol.10, p.4603, 2016. ,
Decrease in Mycobacterium ulcerans disease (Buruli ulcer) in the Lalo District of Bénin (west Africa), BMC Infect Dis, vol.19, p.247, 2019. ,
Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial, Lancet Infect Dis, vol.18, pp.650-56, 2018. ,
Increasing experience with primary oral medical therapy for Mycobacterium ulcerans disease in an Australian cohort, Antimicrob Agents Chemother, vol.60, pp.2692-95, 2016. ,
Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients, Intern Med J, vol.47, pp.1011-1030, 2017. ,
Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy, Trop Med Int Health, vol.21, pp.1191-96, 2016. ,
Six versus eight weeks of antibiotics for small Mycobacterium ulcerans lesions in Australian patients, Clin Infect Dis, 2019. ,
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection, Antimicrob Agents Chemother, vol.54, pp.3878-83, 2010. ,
Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice, Antimicrob Agents Chemother, vol.47, pp.1228-1260, 2003. ,
Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease, J Clin Microbiol, vol.52, pp.1246-1295, 2014. ,
Shortercourse treatment for Mycobacterium ulcerans disease with highdose rifamycins and clofazimine in a mouse model of Buruli ulcer, PLoS Negl Trop Dis, vol.12, p.6728, 2018. ,
Shortening buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting Mycobacterium ulcerans gene decay, Antimicrob Agents Chemother, vol.63, pp.426-445, 2019. ,
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer, Nat Commun, vol.9, pp.5370-79, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01975358